Plain-English translation of NCT07561892 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adding silibinin—a compound derived from milk thistle that may help protect the liver and fight cancer cells—alongside standard chemotherapy drugs (daunorubicin or idarubicin) works better than chemotherapy alone. Researchers want to see if this medication improves how well the treatment works and how safe it is for people newly diagnosed with acute myeloid leukemia (a serious blood cancer, excluding one specific subtype).
Standard chemotherapy for this blood cancer can sometimes damage the liver, and laboratory research suggests this medication might both protect liver health and help fight cancer cells more effectively. This trial will find out whether adding this treatment to standard chemotherapy actually helps patients in real life.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive chemotherapy (either daunorubicin or idarubicin) given intravenously for 3 days. Half of participants will also receive the supplement silibinin by mouth three times daily alongside the chemotherapy, while the other half will receive chemotherapy alone. You will be randomly assigned to one of these two groups, and researchers will monitor how well the treatment works, track side effects, and measure your recovery over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China